Oncolytics Biotech (ONCY) EBITDA (2009 - 2026)
Oncolytics Biotech (ONCY) posted quarterly EBITDA of -$10.6 million for Q3 2025, down 52.71% year-over-year from -$22.5 million in Q3 2024, and down 121.27% quarter-over-quarter from -$4.8 million in Q2 2025.
Oncolytics Biotech (ONCY) EBITDA (2009 - 2026) Analysis & Trends
Oncolytics Biotech (ONCY) has reported EBITDA for 17 consecutive years, with -$10.6 million the latest figure, recorded in Q3 2025.
- In Q3 2025, EBITDA fell 52.71% year-over-year to -$10.6 million; the TTM figure through Sep 2025 stood at -$28.1 million (up 50.94% YoY), while the FY2025 annual figure was -$28.7 million, down 12.42% from the prior year.
- EBITDA declined to -$10.6 million in Q3 2025 per ONCY's latest filing, from -$4.8 million in the prior quarter.
- Across five years, EBITDA topped out at $6.0 million in Q2 2021 and bottomed at -$37.8 million in Q4 2023.
- Historically, EBITDA has averaged -$8.3 million across 5 years, with a median of -$5.2 million in 2024.
- On a YoY basis, EBITDA climbed as much as 218.64% in 2021 and fell as far as 229.96% in 2021.
- Oncolytics Biotech's EBITDA stood at -$35.6 million in 2021, then rose by 15.42% to -$30.1 million in 2022, then fell by 25.61% to -$37.8 million in 2023, then jumped by 84.93% to -$5.7 million in 2024, then tumbled by 86.56% to -$10.6 million in 2025.
- Business Quant data shows ONCY's EBITDA at -$10.6 million in Q3 2025, -$4.8 million in Q2 2025, and -$5.7 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.41 Bn | 130.56 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 86.12 Bn | 78.12 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 64.41 Bn | 59.23 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 57.56 Bn | 52.43 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 42.06 Bn | 36.96 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 30.95 Bn | 27.65 Bn | 992.69 Mn | 231.44 Mn |
| 7 | BioNTech SE | 27.48 Bn | 9.09 Bn | 668.28 Mn | -375.75 Mn |
| 8 | Insmed | 27.31 Bn | 26.15 Bn | 358.27 Mn | -1.55 Mn |
| 9 | Royalty Pharma | 27.04 Bn | 26.20 Bn | - | 133.12 Mn |
| 10 | Oncolytics Biotech | 96.21 Mn | 96.21 Mn | - | -9.38 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -9.38 Mn |
| Sep 30, 2025 | -10.62 Mn |
| Jun 30, 2025 | -4.80 Mn |
| Dec 31, 2024 | -5.69 Mn |
| Sep 30, 2024 | -6.96 Mn |
| Jun 30, 2024 | -5.20 Mn |
| Dec 31, 2023 | -37.79 Mn |
| Sep 30, 2023 | -7.27 Mn |
| Jun 30, 2023 | -5.56 Mn |
| Mar 31, 2023 | 4.69 Mn |
| Dec 31, 2022 | -30.08 Mn |
| Sep 30, 2022 | -3.16 Mn |
| Jun 30, 2022 | -3.89 Mn |
| Mar 31, 2022 | 5.41 Mn |
| Dec 31, 2021 | -35.57 Mn |
| Sep 30, 2021 | 3.82 Mn |
| Jun 30, 2021 | 5.95 Mn |
| Mar 31, 2021 | -5.11 Mn |
| Dec 31, 2020 | 27.37 Mn |
| Sep 30, 2020 | -5.10 Mn |